NFL Biosciences SA (ALNFL.PA)
EUR 1.88
(-2.59%)
EUR 1.88
(-2.59%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -3.74 Million EUR | -53.28% |
| 2022 | -2.44 Million EUR | -149.78% |
| 2021 | -978.24 Thousand EUR | -267.09% |
| 2020 | -266.48 Thousand EUR | 0.55% |
| 2019 | -267.96 Thousand EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -731.5 Thousand EUR | 55.25% |
| 2023 FY | -3.74 Million EUR | -53.28% |
| 2023 Q4 | -1.63 Million EUR | 22.54% |
| 2023 Q2 | -2.11 Million EUR | -53.82% |
| 2022 Q4 | -1.37 Million EUR | -28.07% |
| 2022 FY | -2.44 Million EUR | -149.78% |
| 2022 Q2 | -1.07 Million EUR | 0.0% |
| 2021 FY | -978.24 Thousand EUR | -267.09% |
| 2021 Q2 | -221.4 Thousand EUR | 0.0% |
| 2020 FY | -266.48 Thousand EUR | 0.55% |
| 2019 FY | -267.96 Thousand EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.51 Million EUR | -6.466% |
| ABIVAX Société Anonyme | -147.74 Million EUR | 97.465% |
| Adocia SA | -21.16 Million EUR | 82.301% |
| Aelis Farma SA | -5.07 Million EUR | 26.241% |
| Biophytis S.A. | -17.02 Million EUR | 78.001% |
| Advicenne S.A. | -7.03 Million EUR | 46.729% |
| genOway Société anonyme | 1.56 Million EUR | 338.934% |
| IntegraGen SA | -171.39 Thousand EUR | -2085.238% |
| Medesis Pharma S.A. | -3.95 Million EUR | 5.405% |
| Neovacs S.A. | -8.74 Million EUR | 57.162% |
| Plant Advanced Technologies SA | 79.16 Thousand EUR | 4830.988% |
| Quantum Genomics Société Anonyme | -3.17 Million EUR | -18.119% |
| Sensorion SA | -22.06 Million EUR | 83.024% |
| Theranexus Société Anonyme | -6.82 Million EUR | 45.145% |
| TME Pharma N.V. | -6.73 Million EUR | 44.396% |
| Valbiotis SA | -7.36 Million EUR | 49.166% |
| TheraVet SA | -1.57 Million EUR | -138.458% |
| Valerio Therapeutics Société anonyme | -20.34 Million EUR | 81.589% |
| argenx SE | -272.91 Million EUR | 98.628% |
| BioSenic S.A. | -28.77 Million EUR | 86.985% |
| Celyad Oncology SA | -8.44 Million EUR | 55.664% |
| DBV Technologies S.A. | -67.26 Million EUR | 94.432% |
| Galapagos NV | 211.69 Million EUR | 101.769% |
| Genfit S.A. | -28.89 Million EUR | 87.037% |
| GeNeuro SA | -14.75 Million EUR | 74.619% |
| Hyloris Pharmaceuticals SA | -15.38 Million EUR | 75.647% |
| Innate Pharma S.A. | -7.57 Million EUR | 50.522% |
| Inventiva S.A. | -110.42 Million EUR | 96.608% |
| MaaT Pharma SA | -19.71 Million EUR | 81.004% |
| MedinCell S.A. | -25.03 Million EUR | 85.041% |
| Nanobiotix S.A. | -39.7 Million EUR | 90.566% |
| Onward Medical N.V. | -36.18 Million EUR | 89.648% |
| Oryzon Genomics S.A. | -3.35 Million EUR | -11.707% |
| OSE Immunotherapeutics SA | -23 Million EUR | 83.717% |
| Oxurion NV | -18.96 Million EUR | 80.255% |
| Pharming Group N.V. | -9.75 Million EUR | 61.611% |
| Poxel S.A. | -35.09 Million EUR | 89.326% |
| GenSight Biologics S.A. | -26.22 Million EUR | 85.715% |
| Transgene SA | -22.32 Million EUR | 83.225% |
| Financière de Tubize SA | 88.15 Million EUR | 104.249% |
| UCB SA | 343 Million EUR | 101.092% |
| Valneva SE | -101.42 Million EUR | 96.307% |
| Vivoryon Therapeutics N.V. | -28.34 Million EUR | 86.785% |